Current Progress in Therapeutic Gene Editing for Monogenic Diseases.

Programmable nucleases allow defined alterations in the genome with ease-of-use, efficiency, and specificity. Their availability has led to accurate a...
NAN Sizes 1 Downloads 10 Views

Recommend Documents

Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.
Over the last decade, pioneering liver-directed gene therapy trials for haemophilia B have achieved sustained clinical improvement after a single systemic injection of adeno-associated virus (AAV) derived vectors encoding the human factor IX cDNA. Th

Monogenic autoinflammatory diseases: Cytokinopathies.
Rapid advances in genetics are providing unprecedented insight into functions of the innate immune system with identification of the mutations that cause monogenic autoinflammatory disease. Cytokine antagonism is profoundly effective in a subset of t

Gene editing and its application for hematological diseases.
The use of precise, rationally designed gene-editing nucleases allows for targeted genome and transcriptome modification, and at present, four major classes of nucleases are being employed: zinc finger nucleases (ZFNs), transcription activator-like e

Current gene therapy trials for vascular diseases.
In the previous gene therapy trials for vascular diseases, safety of the therapies has been demonstrated with some evidence for clinical benefits. In the future, it will be important to also test the potential clinical benefits of the treatments in r

Targeting P2 receptors--current progress in treating musculoskeletal diseases.
It is widely recognized that purinergic signalling, extracellular nucleotides acting at purinergic receptors, is the most primitive and ubiquitous signalling system participating in numerous biological processes in almost all tissue types. The P2 rec

Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.
Significant progress has been made in nanomedicine, primarily in the form of nanoparticles, for theranostic applications to various diseases. A variety of materials, both organic and inorganic, have been used to develop nanoparticles with promise to

Uromodulin: from monogenic to multifactorial diseases.
Uromodulin, the major protein secreted in normal urine, is exclusively produced in the thick ascending limb (TAL) cells of the kidney. The exact role uromodulin (UMOD) plays in renal physiology remains enigmatic. UMOD has been linked to water/electro

Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection.
Chronic hepatitis B is still a major public health issue despite the successful prophylactic vaccination attempts. Chronicity of hepatitis B virus (HBV) is mainly due to its ability to debilitate host's immune system. Therefore, major measures have b

Clinical Considerations of Preimplantation Genetic Diagnosis for Monogenic Diseases.
The aim of this study was to explore factors contribute to the success of PGD cycles for monogenic diseases.